Clinical features and latency intervals from first cytotoxic therapy to presentation with t-MDS/t-AML
. | . | Latency, mo . | . | . | |
|---|---|---|---|---|---|
| Clinical feature . | No. patients . | Median . | IQR . | P . | |
| Primary diagnosis | .01* | ||||
| No malignancy | 18 | 130 | 54-228 | — | |
| Hematologic malignancy | 167 | 64 | 40-97 | — | |
| Hodgkin disease | 75 | 62 | 42-85 | — | |
| Non-Hodgkin lymphoma | 69 | 68 | 40-115 | — | |
| Myeloma | 22 | 52 | 34-72 | — | |
| Other | 1 | 122 | — | — | |
| Solid tumor | 109 | 55 | 25-105 | — | |
| Breast | 30 | 65 | 25-107 | — | |
| Ovary | 12 | 53 | 18-74 | — | |
| Prostate | 12 | 54 | 18-82 | — | |
| Lung | 9 | 28 | 19-43 | — | |
| Cervix | 7 | 136 | 79-396 | — | |
| Other | 39 | 52 | 33-109 | — | |
| Primary therapy | .19 | ||||
| CT only | 116 | 53 | 33-106 | — | |
| RT only | 42 | 68 | 25-135 | — | |
| CMT | 135 | 67 | 45-104 | — | |
| Age range at primary diagnosis, y | <.0001 | ||||
| 3-36 | 73 | 72 | 46-134 | — | |
| 37-50 | 73 | 82 | 48-151 | — | |
| 51-61 | 70 | 54 | 28-77 | — | |
| 62-83 | 78 | 47 | 24-82 | — | |
| Presentation of t-MDS/t-AML | .04† | ||||
| t-MDS | 220‡ | 65 | 39-110 | — | |
| t-MDS→unknown | 53 | 73 | 44-115 | — | |
| t-MDS only | 71 | 58 | 35-96 | — | |
| t-MDS→t-AML | 96 | 65 | 36-115 | — | |
| t-AML | 74 | 54 | 28-88 | — | |
. | . | Latency, mo . | . | . | |
|---|---|---|---|---|---|
| Clinical feature . | No. patients . | Median . | IQR . | P . | |
| Primary diagnosis | .01* | ||||
| No malignancy | 18 | 130 | 54-228 | — | |
| Hematologic malignancy | 167 | 64 | 40-97 | — | |
| Hodgkin disease | 75 | 62 | 42-85 | — | |
| Non-Hodgkin lymphoma | 69 | 68 | 40-115 | — | |
| Myeloma | 22 | 52 | 34-72 | — | |
| Other | 1 | 122 | — | — | |
| Solid tumor | 109 | 55 | 25-105 | — | |
| Breast | 30 | 65 | 25-107 | — | |
| Ovary | 12 | 53 | 18-74 | — | |
| Prostate | 12 | 54 | 18-82 | — | |
| Lung | 9 | 28 | 19-43 | — | |
| Cervix | 7 | 136 | 79-396 | — | |
| Other | 39 | 52 | 33-109 | — | |
| Primary therapy | .19 | ||||
| CT only | 116 | 53 | 33-106 | — | |
| RT only | 42 | 68 | 25-135 | — | |
| CMT | 135 | 67 | 45-104 | — | |
| Age range at primary diagnosis, y | <.0001 | ||||
| 3-36 | 73 | 72 | 46-134 | — | |
| 37-50 | 73 | 82 | 48-151 | — | |
| 51-61 | 70 | 54 | 28-77 | — | |
| 62-83 | 78 | 47 | 24-82 | — | |
| Presentation of t-MDS/t-AML | .04† | ||||
| t-MDS | 220‡ | 65 | 39-110 | — | |
| t-MDS→unknown | 53 | 73 | 44-115 | — | |
| t-MDS only | 71 | 58 | 35-96 | — | |
| t-MDS→t-AML | 96 | 65 | 36-115 | — | |
| t-AML | 74 | 54 | 28-88 | — | |
— indicates not applicable; t-MDS→unknown, patients with t-MDS for whom no further follow-up data were available regarding progression to t-AML before death.
For comparison of the 3 major categories of no malignancy, hematologic malignancy, and solid tumor.
For pairwise comparison of t-MDS and t-AML.
Data regarding latency interval were missing for 4 patients with t-MDS.